Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Benzinga_recent_news

01/28

Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday closed around 32% lower after the management update and trial update. Mani Mohindru, a board member since 2021, was named interim CEO, effective ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2606053718"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606053718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606053718?lang=zh_TW&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/28/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-28 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606053718","market":"us","top_or_hot":-1,"title":"Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus","media":"Benzinga_recent_news","content":"<div>\n<p>Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday closed around 32% lower after the management update and trial update.\nMani Mohindru, a board member since 2021, was named interim CEO, effective ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus\">网页链接</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga_recent_news</strong><span class=\"h-time small\">2026-01-28 19:23</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday closed around 32% lower after the management update and trial update.\nMani Mohindru, a board member since 2021, was named interim CEO, effective ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus\">Benzinga_recent_news</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus","article_id":"2606053718","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/28/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/01/50183164/cardiff-oncology-stock-plunges-after-sudden-leadership-change-narrowed-trial-focus","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606053718","pubTimestamp":1769599380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Cardiff Oncology shares fell 32% after a sudden CEO and CFO exit, trial strategy changes, and a negative analyst update that cut success odds and market potential.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRDF":"Cardiff Oncology, Inc."},"translate_title":"领导层突然变动、试验重点缩小后，卡迪夫肿瘤公司股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRDF":1},"content_text":"Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday closed around 32% lower after the management update and trial update.\nMani Mohindru, a board member since 2021, was named interim CEO, effective immediately. Mark Erlander, CEO, and James Levine, CFO, have stepped down.\nTo maintain financial continuity, Brigitte Lindsay was promoted to Chief Accounting Officer. She has been with the company for more than 14 years and most recently served as Senior Vice President of Finance. Cardiff Oncology has begun a search for a permanent CEO and CFO.\n「The leadership transition reflects the Company’s focus on execution and clinical advancement as its programs mature,」 the company said in a press release on Tuesday.\nConcurrently, Cardiff Oncology announced an update from CRDF-004, a randomized dose-finding Phase 2 trial evaluating onvansertib in combination with standard of care (SoC) regimens (FOLFIRI/bevacizumab (bev) or FOLFOX/bev) in patients with first-line (1L) RAS-mutated metastatic colorectal cancer (mCRC).\nIn an intent-to-treat analysis, the clinical data show dose-dependent benefits across multiple efficacy measures in patients receiving onvansertib with FOLFIRI/bev compared to patients receiving either the SoC regimen.\nThe 30 mg dose group demonstrated a 72.2% confirmed objective response rate versus 43.2% in the standard of care group, approaching statistical significance with a p-value of 0.051.\nProgression-free survival data also showed improvement, with the 30 mg onvansertib plus FOLFIRI/bevacizumab group achieving statistical significance compared to standard care (p-value = 0.048). The median progression-free survival was not yet reached in the onvansertib treatment groups at the time of analysis.\nIn this trial, onvansertib with FOLFIRI/bev also performed better than onvansertib with FOLFOX/bev.\nBased on these results, the company has selected the 30 mg dose of onvansertib with FOLFIRI/bev to bring forward in a registrational trial in 1L patients with RAS-mutated mCRC.\nCardiff Oncology plans to initiate a registrational program later this year, pending finalization of the trial design in consultation with the FDA, in which the company expects to compare onvansertib with FOLFIRI/bev to SoC regimens, FOLFIRI/bev, or FOLFOX/bev.\nOnvansertib in combination with both chemo/bev regimens was well-tolerated. There were no major or unexpected toxicities observed and no additive adverse events. Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event across both the onvansertib combination and standard of care arms.\nWilliam Blair on Tuesday wrote, 「Overall, given the abrupt management changes in the absence of a smooth transition plan, coupled with a narrowed focus on onvansertib in combination with FOLFIRI, as opposed to both FOLFIRI and FOLFOX, we view the update slants in a negative direction.」\nAnalyst Andy Hsieh reduced the probability of success to 45% from 50% previously. Assuming regulatory alignment with the FDA, focusing on the onvansertib plus FOLFIRI and Avastin reduces the total addressable market in the frontline setting to 12%-20% from 40%-50% previously.\nWilliam Blair maintains the Outperform rating.\nPrice Action: CRDF closed 31.9% lower to $2 on Tuesday, close to the lower end of the 52-week range of $1.85-$4.99 according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}